Clinical Trials
Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data
Eli Lilly said that its weight-loss medicine Zepbound, when used in combination with psoriasis treatment Taltz, delivered stronger outcomes than Taltz alone in patients living with both psoriasis and obesity in a late-stage study.
The psoriasis trial enrolled 274 patients...
Business & Industry
J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant
Johnson & Johnson announced that it plans to invest more than $1 billion to construct a new cell therapy facility in Pennsylvania. The move forms part of the company’s broader strategy, unveiled last year, to expand its U.S. manufacturing...
News
Precision Cellular Analysis Powering the Next Generation
Biopharmaceutical innovation increasingly depends on understanding biology at the cellular level. As therapies become more targeted and personalized, researchers must analyze how individual cells respond to treatment, interact with their environment, and signal changes within complex systems. Precision cellular...
Business & Industry
FDA Approves Monthly Rybrevant Faspro for EGFR-Mutated NSCLC
Johnson & Johnson (J&J) has obtained approval from the US Food and Drug Administration (FDA) for a revised dosing schedule of Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), introducing a once-monthly administration option for patients with advanced, epidermal growth factor receptor...
BioPharma
European Commission Approves Exdensur – depemokimab
On February 17, 2026, GSK plc announced that the European Commission approves Exdensur - depemokimab in two indications -
As an add-on maintenance treatment when it comes to critical asthma with type 2 inflammation that stands characterised by a blood eosinophil...
Business & Industry
Sanofi to Expand Its Global Capability Centre in Hyderabad
In a move that is sure to create a stir within the Asia pharma circle, Sanofi Healthcare India - SHIPL is going ahead and expanding its GCC- global capability centre in Hyderabad, Telangana State with another 2.7 lakh sq.ft....
Business & Industry
Gilead Secures GH31 Global Rights in $80M Oncology Deal
Gilead Sciences has added another synthetic lethal asset to its oncology portfolio, agreeing to pay $80 million upfront to obtain global rights to a clinic-ready cancer therapy from China-based Genhouse Bio.
Headquartered in Suzhou, Genhouse Bio has been advancing its...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read